ANI Pharmaceuticals ANIP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $237.46M-3.9% | $247.06M+8.4% | $227.81M+7.8% | $211.37M+7.2% | $197.12M+3.4% | ||
| $93.58M-6.7% | $100.27M+7.4% | $93.39M+25.2% | $74.62M+2.2% | $73.04M-9.0% | ||
| $143.88M-2.0% | $146.79M+9.2% | $134.42M-1.7% | $136.76M+10.2% | $124.09M+12.5% | ||
| 60.6%+1.2pp | 59.4%+0.4pp | 59%-5.7pp | 64.7%+1.8pp | 62.9%+5.1pp | ||
| $10.6M-13.5% | $12.26M-0.3% | $12.3M-25.6% | $16.54M+56.5% | $10.56M-36.5% | ||
| $73.66M-11.0% | $82.79M+8.0% | $76.66M-6.3% | $81.77M+6.9% | $76.53M+9.8% | ||
| $198.57M-6.5% | $212.29M+10.8% | $191.57M-3.0% | $197.48M+15.5% | $170.93M-12.3% | ||
| $38.89M+11.9% | $34.77M-4.1% | $36.24M+161% | $13.89M-47.0% | $26.19M— | ||
| 16.4%+2.3pp | 14.1%-1.8pp | 15.9%+9.3pp | 6.6%-6.7pp | 13.3%— | ||
| -$3.77M+14.6% | -$4.41M+6.7% | -$4.73M+13.1% | -$5.44M+0.8% | -$5.48M+8.8% | ||
| -$651K-177% | $850K+200% | -$853K-149% | $1.74M+778% | $198K+114% | ||
| $40.22M+27.8% | $31.48M-6.9% | $33.8M+221% | $10.53M-47.3% | $19.99M+245% | ||
| $10.73M+169% | $3.99M-44.5% | $7.18M+264% | $1.98M-54.1% | $4.31M+224% | ||
| $29.49M+7.3% | $27.49M+3.3% | $26.62M+211% | $8.55M-45.5% | $15.68M+253% | ||
| 12.4%+1.3pp | 11.1%-0.6pp | 11.7%+7.6pp | 4%-3.9pp | 8%+13.3pp | ||
| $0— | $0-100% | $344K-15.5% | $407K+0.2% | $406K0.0% | ||
| $1.28+9.4% | $1.17+3.5% | $1.13+214% | $0.36-47.8% | $0.69+225% | ||
| $1.31+5.6% | $1.24+4.2% | $1.19+222% | $0.37-47.1% | $0.70+227% | ||
| 21.5M+1.5% | 21.2M+0.6% | 21.1M+3.9% | 20.3M+1.3% | 20M+3.8% | ||
| 20.9M+4.3% | 20.1M-0.1% | 20.1M+1.2% | 19.8M+1.2% | 19.6M+1.5% | ||
| $5.75M+2,007% | $273K-91.3% | $3.14M+846% | $332K+136% | -$921K— | ||
| -$3.77M+14.6% | -$4.41M+6.7% | -$4.73M+13.1% | -$5.44M+0.8% | -$5.48M+8.8% | ||
| -$182K+96.8% | -$5.73M+60.4% | -$14.47M-1,233% | $1.28M+111% | -$12.09M-539% | ||
| -$651K-177% | $850K+200% | -$853K-149% | $1.74M+778% | $198K+114% | ||
| $237.46M-3.9% | $247.06M+8.4% | $227.81M+7.8% | $211.37M+7.2% | $197.12M+3.4% | ||
| $38.89M+11.9% | $34.77M-4.1% | $36.24M+161% | $13.89M-47.0% | $26.19M+232% | ||
| $59.81M+4.2% | $57.38M-2.5% | $58.87M+58.4% | $37.17M-24.3% | $49.09M+1,639% | ||
| $59.81M+4.2% | $57.38M-2.5% | $58.87M+58.4% | $37.17M-24.3% | $49.09M+1,639% | ||
| 25.2%+2.0pp | 23.2%-2.6pp | 25.8%+8.3pp | 17.6%-7.3pp | 24.9%+23.4pp | ||
| $38.89M+11.9% | $34.77M-4.1% | $36.24M+161% | $13.89M-47.0% | $26.19M+232% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ANI Pharmaceuticals's revenue?
- ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.
- Is ANI Pharmaceuticals profitable?
- ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
- What is ANI Pharmaceuticals's earnings per share?
- ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
